

Reimbursement Policy

Cervical Cancer Screening

[POLICY DESCRIPTION](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

I. Policy Description

Cervical cancer screening detects cervical precancerous lesions and cancer through cytology, human papillomavirus (HPV) testing, and if needed, colposcopy.¹ The principal screening test to detect cancer in asymptomatic individuals with a cervix is the Papanicolaou (Pap) smear. It involves cells being scraped from the cervix during a pelvic examination and spread onto a slide. The slide is then sent to an accredited laboratory to be stained, observed, and interpreted.²

Human papilloma virus (HPV) has been associated with development of cervical intraepithelial neoplasia, and FDA-approved HPV tests detecting the presence of viral DNA from high-risk strains have been developed and validated as an adjunct primary cancer screening method.²

For additional information on testing for HPV, please refer to AHS-G2157-Diagnostic Testing of Common Sexually Transmitted Infections.

Terms such as male and female are used when necessary to refer to sex assigned at birth.

II. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the "Applicable State and Federal Regulations" section of this policy document.

The criteria below are based on recommendations by the U.S. Preventive Services Task Force, The National Cancer Institute, NCCN, The American Society for Colposcopy and Cervical Pathology, The American Cancer Society, The American Society for Clinical Pathology, and the American College of Obstetricians and Gynecologists. Within these coverage criteria, "individual(s)" is specific to individuals with a cervix.

- 1) For immunocompromised or immunosuppressed individuals, **any one** of the following cervical cancer screening techniques **MEETS COVERAGE CRITERIA**:
 - a) Annual cervical cytology testing for individuals of all ages.

Reimbursement Policy

- b) Co-testing (cervical cytology and high-risk HPV [hr-HPV] testing) once every year for individuals 30 years of age or older.
 - 2) For individuals 21 to 29 years of age, cervical cancer screening once every year using conventional or liquid-based Papanicolaou (Pap) smears **MEETS COVERAGE CRITERIA**.
 - 3) For individuals 30 to 65 years of age, **any one** of the following cervical cancer screening techniques **MEETS COVERAGE CRITERIA**:
 - a) Conventional or liquid-based Pap smear once every year.
 - b) Cervical cancer screening using the hr-HPV test alone once every year.
 - c) Co-testing (cytology with concurrent hr-HPV testing) once every year.
 - 4) For individuals who are over 65 years of age **and** who are considered high-risk (individuals with a high-grade precancerous lesion or cervical cancer, individuals with in utero exposure to diethylstilbestrol (DES)), cervical cancer screening at the frequency described in coverage criterion 3 **MEETS COVERAGE CRITERIA**.
 - 5) For individuals who are pooled hr-HPV positive, nucleic acid testing for high-risk strains HPV-16 and HPV-18 **MEETS COVERAGE CRITERIA**.
 - 6) For individuals 65 years of age or younger, annual cervical cancer screening by Pap smear or hr-HPV testing **MEETS COVERAGE CRITERIA** in **any** of the following situations:
 - a) For individuals who had a previous cervical cancer screen with an abnormal cytology result and/or who was positive for HPV.
 - b) For individuals at high-risk for cervical cancer (organ transplant, exposure to the drug DES).
- NOTE:** Allow all PAP & HPV testing for all ages once per calendar year regardless of diagnosis code.
- 7) For all situations not addressed above, cervical cancer screening (i.e., cervical cytology, hr-HPV testing) for individuals less than 21 years of age **DOES NOT MEET COVERAGE CRITERIA**.
 - 8) For individuals over 65 years of age who are not immunocompromised, immunosuppressed, or who are not considered high-risk for developing cervical cancer (i.e., had abnormal cytology or previously tested positive for hr-HPV), routine cervical cancer screening **DOES NOT MEET COVERAGE CRITERIA**.

Reimbursement Policy

9) For individuals who have undergone surgical removal of the uterus and cervix and who have no history of cervical cancer or precancer, cervical cancer screening (at any age) **DOES NOT MEET COVERAGE CRITERIA.**

10) Testing for low-risk HPV **DOES NOT MEET COVERAGE CRITERIA.**

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.

11) For cervical cancer screening, all other technologies not discussed above **DO NOT MEET COVERAGE CRITERIA.**

III. Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <https://www.cms.gov/medicare-coverage-database/search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

The FDA has approved the APTIMA HPV 16 18/45 Genotype Assay, a nucleic acid amplification test (NAAT), for the qualitative detection of mRNA for HPV 16, 18, and 45 from Gen-Probe Incorporated on October 12, 2012; however, this test cannot distinguish between 18 and 45. Previously, on October 28, 2011, the FDA-approved Gen-Probe Incorporated's APTIMA HPV Assay, an NAAT that tests for 14 high-risk types of HPV but is unable to distinguish between the 14 types.

Hologic, Inc. has two FDA-approved HPV NAAT tests—Cervista HPV 16/18 and Cervista HPV HR and GENFIND DNA Extraction Kit. Both were approved on March 12, 2009. The former is a fluorescent, isothermal-based reaction that detects HPV 16 and 18 whereas the latter screens for DNA from the 14 high-risk HPV strains.³⁸

Reimbursement Policy

The COBAS HPV test by Roche Molecular Systems, Inc. was approved by the FDA on April 19, 2011, as a NAAT for 14 high-risk types of HPV. This test can specifically identify HPV 16 and 18 but cannot distinguish from the other 12 types of HPV. On July 2, 2018, the FDA released an approval order statement (P100020/S025) “for an expansion of the intended use for the FDA-approved Cobas HPV test to include cervical specimens collected in SurePath Preservative Fluid as a specimen type.”³⁹ This approval allows for the Cobas HPV test to be used as a first-line cervical cancer screening using the SurePath preservative, a medium often used for Pap tests.⁴⁰ In 2020, the Cobas HPV was FDA-approved for use on Cobas 6800/8800 Systems.⁴¹

On February 12, 2018, the FDA-approved the BD Onclarity™ HPV Assay which detects 14 high-risk HPV genotypes including high-risk strains 16 and 18. “The BD Onclarity HPV Assay is a qualitative in vitro test for the detection of Human Papillomavirus in cervical specimens collected by a clinician using an endocervical brush/spatula combination or broom and placed in BD SurePath vial.”³⁸

For more information regarding HPV, please refer to AHS-G2157 Diagnostic testing of STIs.

IV. Applicable CPT/HCPCS Procedure Codes

CPT	Code Description
87623	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (e.g., 6, 11, 42, 43, 44)
87624	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result
87625	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed
87626	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), separately reported high-risk types (e.g., 16, 18, 31, 45, 51, 52) and high-risk pooled result(s)
88141	Cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician
88142	Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision
88143	Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with manual screening and rescreening under physician supervision
88147	Cytopathology smears, cervical or vaginal; screening by automated system under physician supervision

Reimbursement Policy

CPT	Code Description
88148	Cytopathology smears, cervical or vaginal; screening by automated system with manual rescreening under physician supervision
88150	Cytopathology, slides, cervical or vaginal; manual screening under physician supervision
88152	Cytopathology, slides, cervical or vaginal; with manual screening and computer-assisted rescreening under physician supervision
88153	Cytopathology, slides, cervical or vaginal; with manual screening and rescreening under physician supervision
88164	Cytopathology, slides, cervical or vaginal (the Bethesda System); manual screening under physician supervision
88165	Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and rescreening under physician supervision
88166	Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening under physician supervision
88167	Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening using cell selection and review under physician supervision
88174	Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; screening by automated system, under physician supervision
88175	Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision
G0123	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision
G0124	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician
G0141	Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician
G0143	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with manual screening and rescreening by cytotechnologist under physician supervision
G0144	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system, under physician supervision

Reimbursement Policy

CPT	Code Description
G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision
G0147	Screening cytopathology smears, cervical or vaginal, performed by automated system under physician supervision
G0148	Screening cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening
G0476	Infectious agent detection by nucleic acid (DNA or RNA); human papillomavirus (hvp), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test
P3000	Screening Papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision
P3001	Screening Papanicolaou smear, cervical or vaginal, up to three smears, requiring interpretation by physician
Q0091	Screening Papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

V. Evidence-based Scientific References

1. Feldman S, Goodman A, Peipert J. Screening for cervical cancer in resource-rich settings. Updated January 29, 2025. <https://www.uptodate.com/contents/screening-for-cervical-cancer-in-resource-rich-settings>
2. Feldman S, Crum C. Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing. Updated October 30, 2024. <https://www.uptodate.com/contents/cervical-cancer-screening-tests-techniques-for-cervical-cytology-and-human-papillomavirus-testing>
3. ACS. Key Statistics for Cervical Cancer. American Cancer Society, Inc. Updated January 16, 2025. <https://www.cancer.org/cancer/cervical-cancer/about/key-statistics.html>
4. William R Robinson. Screening for Cervical Cancer in Resource-Risk Settings. Updated Januray 9,2025 <https://www.uptodate.com/contents/screening-for-cervical-cancer-in-resource-rich-settings>
5. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. *CA Cancer J Clin.* Sep 2020;70(5):321-346. doi:10.3322/caac.21628
6. William R Robinson. Screening for cervical cancer in patients with HIV infection and other immunocompromised states. Updated October 4, 2024.

Reimbursement Policy

<https://www.uptodate.com/contents/screening-for-cervical-cancer-in-patients-with-hiv-infection-and-other-immunocompromised-states>

7. Health T. Teal Wand™ for At-Home Cervical Cancer Screening.
<https://www.getteal.com/teal-wand>
8. Crane L, Jennings A, Fitzpatrick MB, et al. Experiences and Preferences Reported with an At-Home Self-Collection Device Compared with In-Clinic Speculum-Based Cervical Cancer Screening in the United States. *Women's Health Reports*. 2025/01/01 2025;6(1):564-575. doi:10.1089/whr.2025.0017
9. Marchand L, Mundt M, Klein G, Agarwal SC. Optimal collection technique and devices for a quality pap smear. *WMJ : official publication of the State Medical Society of Wisconsin*. Aug 2005;104(6):51-5.
10. Mendez K, Romaguera J, Ortiz AP, Lopez M, Steinau M, Unger ER. Urine-based human papillomavirus DNA testing as a screening tool for cervical cancer in high-risk women. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*. Feb 2014;124(2):151-5. doi:10.1016/j.ijgo.2013.07.036
11. Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. *BMJ (Clinical research ed)*. Sep 16 2014;349:g5264. doi:10.1136/bmj.g5264
12. NCI. Cervical Cancer Screening (PDQ®)—Health Professional Version. National Institutes of Health. Updated April 21, 2023. <https://www.cancer.gov/types/cervical/hp/cervical-screening-pdq>
13. Sabeena S, Kuriakose S, Binesh D, et al. The Utility of Urine-Based Sampling for Cervical Cancer Screening in Low-Resource Settings. *Asian Pac J Cancer Prev*. Aug 1 2019;20(8):2409-2413. doi:10.31557/apjcp.2019.20.8.2409
14. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)) - Cervical Cancer Version 3.2025. Updated February 10, 2025.
https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf
15. Sasieni P, Castanon A, Cuzick J. Screening and adenocarcinoma of the cervix. *International journal of cancer*. Aug 1 2009;125(3):525-9. doi:10.1002/ijc.24410
16. Dahlstrom LA, Ylitalo N, Sundstrom K, et al. Prospective study of human papillomavirus and risk of cervical adenocarcinoma. *International journal of cancer*. Oct 15 2010;127(8):1923-30. doi:10.1002/ijc.25408
17. Chen HC, Schiffman M, Lin CY, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. *Journal of the National Cancer Institute*. Sep 21 2011;103(18):1387-96. doi:10.1093/jnci/djr283
18. Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. *Jama*. Jul 3 2018;320(1):43-52. doi:10.1001/jama.2018.7464

Reimbursement Policy

19. Massad LS. Replacing the Pap Test With Screening Based on Human Papillomavirus Assays. *Jama*. Jul 3 2018;320(1):35-37. doi:10.1001/jama.2018.7911
20. Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Weyrich MS. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *Jama*. Aug 21 2018;320(7):687-705. doi:10.1001/jama.2018.10400
21. Bonde JH, Sandri MT, Gary DS, Andrews JC. Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review. *J Low Genit Tract Dis*. Jan 2020;24(1):1-13. doi:10.1097/lgt.0000000000000494
22. Pry JM, Manasyan A, Kapambwe S, et al. Cervical cancer screening outcomes in Zambia, 2010-19: a cohort study. *Lancet Glob Health*. Jun 2021;9(6):e832-e840. doi:10.1016/s2214-109x(21)00062-0
23. Dilley S, Huh W, Blechter B, Rositch AF. It's time to re-evaluate cervical Cancer screening after age 65. *Gynecol Oncol*. Jul 2021;162(1):200-202. doi:10.1016/j.ygyno.2021.04.027
24. Qin J, Holt HK, Richards TB, Saraiya M, Sawaya GF. Use Trends and Recent Expenditures for Cervical Cancer Screening-Associated Services in Medicare Fee-for-Service Beneficiaries Older Than 65 Years. *JAMA Intern Med*. Jan 1 2023;183(1):11-20. doi:10.1001/jamainternmed.2022.5261
25. Winer RL, Lin J, Anderson ML, et al. Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits: A Randomized Clinical Trial. *Jama*. Nov 28 2023;330(20):1971-1981. doi:10.1001/jama.2023.21471
26. USPSTF. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement USPSTF Recommendation: Screening for Cervical Cancer USPSTF Recommendation: Screening for Cervical Cancer. *Jama*. 2018;320(7):674-686. doi:10.1001/jama.2018.10897
27. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. *J Low Genit Tract Dis*. Apr 2020;24(2):102-131. doi:10.1097/LGT.0000000000000525
28. Moscicki AB, Flowers L, Huchko MJ, et al. Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection. *J Low Genit Tract Dis*. Apr 2019;23(2):87-101. doi:10.1097/lgt.0000000000000468
29. Wentzensen N, Massad LS, Clarke MA, et al. Self-Collected Vaginal Specimens for HPV Testing: Recommendations From the Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee. *J Low Genit Tract Dis*. Apr 1 2025;29(2):144-152. doi:10.1097/lgt.0000000000000885
30. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. *J Low Genit Tract Dis*. Apr 2015;19(2):91-6. doi:10.1097/lgt.0000000000000103
31. ACOG. Updated Cervical Cancer Screening Guidelines. Updated April 12, 2021. <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines>

Reimbursement Policy

32. ACOG. Updated Guidelines for Management of Cervical Cancer Screening Abnormalities. Updated October 9, 2020. <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/10/updated-guidelines-for-management-of-cervical-cancer-screening-abnormalities>
33. EASC. Guidlines Version 12.0. <https://www.eacsociety.org/guidelines/eacs-guidelines/>
34. HHS. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. Updated July 9, 2024. <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/human>
35. CDC. HPV-Associated Cancers and Precancers. Updated July 22, 2021. <https://www.cdc.gov/std/treatment-guidelines/hpv-cancer.htm>
36. AAFP. Choosing Wisely Recommendations. <https://www.aafp.org/pubs/afp/collections/choosing-wisely/28.html>
37. Shastri SS, Temin S, Almonte M, et al. Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Guideline Update. *JCO Glob Oncol*. Sep 2022;8:e2200217. doi:10.1200/GO.22.00217
38. FDA. BD ONCLARITY HPV ASSAY. <https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pma&id=391601>
39. FDA. PMA Monthly approvals from 7/1/2018 to 7/31/2018. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=409848>
40. Rice SL, Editor. Cobas HPV test approved for first-line screening using SurePath preservative fluid. *CAP Today*. August 2018.
41. FDA. Cobas HPV For Use On The Cobas 6800/8800 Systems. <https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pma&id=448383>

VI. Revision History

Revision Date	Summary of Changes
09/04/2025	Reviewed and Updated: Updated the background, guidelines and recommendations, and evidence-based scientific references. Literature review necessitated the following changes to coverage criteria: CC1, 3, 5, 6, 7, and 8 were edited for clarity and consistency. Split former CC10 into two CC, one to address low-risk HPV testing (CC10), which has sufficient evidence indicating that low-risk HPV testing should not be performed, and one to address other technologies to screen for cervical cancer, which would have insufficient evidence to support allowing the test. These CC now read: “10) Testing for low-risk HPV DOES NOT MEET COVERAGE CRITERIA. 11) For cervical cancer screening, all other technologies not discussed above DO NOT MEET COVERAGE CRITERIA.”

Reimbursement Policy

12/04/2024	Off-cycle coding modification: Added CPT code 87626 (effective date 1/1/2025) Removed CPT code 0500T (deleted code; effective date 1/1/2025) Revised code description for CPT code 87624 (effective date 1/1/2025)
------------	--